Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholesterol-Lowering Atherosclerosis Study (CLAS)
NCT00000599Phase 3
Key facts
- Status
- Completed
- Start
- Jun 1980
- Sponsor
- National Heart, Lung, and Blood Institute
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Drugs
- colestipolniacin
- Conditions
- atherosclerosiscoronary artery disease (CAD)
01
Overview
Phase 3, randomised, double-blind trial of colestipol and niacin in atherosclerosis and coronary artery disease (CAD) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Global change score of atherosclerosis at 2 years. Started Jun 1980; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Drug Group
Colestipol (30g) + Niacin (3-12g) daily + Fat-restricted diet
Placebo Group
Placebo + Fat-restricted diet
03
Endpoints
Primary
Global change score of atherosclerosis
Secondary
Plasma lipid and lipoprotein cholesterol levels
Beyond the preview
Go deeper on NCT00000599.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000599.